Blockchain Registration Transaction Record

Novus Reports 18.1% EBITDA Surge, Pioneers Cannabis Health Plan Model

Novus Cannabis MedPlan reports 18.1% EBITDA growth and 8.85% revenue increase for 9M 2025, showcasing its innovative health plans with cannabis benefits and non-dilutive capital strategy.

This news highlights a significant evolution in the healthcare and cannabis industries, where Novus's model addresses critical barriers to patient access and financial integration. As cannabis gains acceptance for medical use, patients often face hurdles in affordability and insurance coverage; Novus's approach, leveraging HSAs and FSAs, directly tackles these issues by creating a compliant pathway for pre-tax healthcare dollars to be used. This matters because it could lower out-of-pocket costs for millions of Americans, potentially expanding access to alternative treatments while setting a precedent for how ancillary businesses can thrive in a federally complex landscape. The company's strong financial performance and non-dilutive strategy also signal stability and growth potential in a volatile sector, offering insights for investors eyeing the intersection of healthcare innovation and cannabis markets.